BioVeda
Home
Investment Policy
People
Investors
Our Companies
Our CEOs
News and Events
2009 News
2010 News
Contact
2009 News
Sep 19
-
Renovo Announces the End of its Offer Period and a Business Restructuring
Sep 10
-
Dynavax Reports FDA Removes Clinical Hold on HEPLISAV Phase 3 Hepatitis B Vaccine
Aug 12
-
Dynavax Announces European Development Strategy for HEPLISAV Hepatitis B Vaccine
May 13
-
Dynavax Awarded Grant to Support Development of TLR Inhibitors in Skin Diseases
Apr 14
-
Lancet Publication by Renovo
Apr 8
-
Kiadis Report ATIR Clinical Data
Apr 6
-
Statement Regarding Possible Offer For Renovo
Mar 13
-
Renovo Announces Encouraging Juvidex Results
Mar 11
-
Dynavax Announces Extension of AstraZeneca Research Collaboration
Mar 11
-
Kiadis Appoints New Chief Operations Officer
Mar 4
-
Dynavax Appoints New Chief Medical Officer
Jan 6
-
Kiadis Appoints New Chief Medical Officer
Your Partner in Asia